|1.||Kikwai, Loice: 3 articles (01/2005 - 01/2004)|
|2.||Singh, Mandip: 3 articles (01/2005 - 01/2004)|
|3.||Armstrong, Cheryl A: 2 articles (01/2005 - 01/2004)|
|4.||Ansel, John C: 2 articles (01/2005 - 01/2004)|
|5.||Babu, R Jayachandra: 2 articles (01/2005 - 01/2004)|
|6.||Kanikkannan, Narayanasamy: 2 articles (01/2004 - 01/2004)|
|7.||Prado, Renata: 1 article (01/2005)|
|8.||Kolot, Alexandra: 1 article (01/2005)|
|9.||Babu, R J: 1 article (01/2004)|
|10.||Jaiani, Lasha T: 1 article (01/2004)|
|1.||Allergic Contact Dermatitis
01/01/2005 - "The in vivo anti-inflammatory activity of Spantide II formulations was evaluated in an allergic contact dermatitis (ACD) mouse model. "
01/01/2004 - "Spantide II is a peptide with a molecular weight of 1670.2 which binds to neurokinin-1 receptor (NKR-1) and blocks proinflammatory activities associated with SP. The aim of this study was to investigate in vitro permeation and distribution of spantide II through hairless rat skin and the anti-inflammatory effect of topically delivered spantide II in an allergic contact dermatitis (ACD) mouse model. "
01/01/2004 - "The current study demonstrates that spantide II can effectively be delivered to epidermis and dermis to exert a significant anti-inflammatory activity on the reduction of inflammation in a mouse model of ACD."
01/01/2004 - "Spantide II is a peptide (MW 1668.76) that specifically binds to neurokinin-1 receptor (NKR-1) and blocks inflammation associated with substance P. "
|3.||Wounds and Injuries (Trauma)
|4.||Salmonella Infections (Salmonellosis)
07/01/1996 - "Increased susceptibility to salmonellosis was not due to 1) spantide II-induced alterations in the uptake of this pathogen from the gut, 2) global spantide II-mediated immune suppression, or 3) nonsubstance P receptor-mediated effects of spantide II on macrophages. "
07/01/1996 - "Mice pretreated with spantide II and then orally inoculated developed advanced salmonellosis and had significantly reduced survival rates compared with mice pretreated with a control peptide. "
07/01/1996 - "Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II."
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
|1.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|3.||6-Cyano-7-nitroquinoxaline-2,3-dione (6 Cyano 7 nitroquinoxaline 2,3 dione)
|4.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|5.||Kainic Acid Receptors (Kainate Receptor)
|6.||Dizocilpine Maleate (Dizocilpine)
|7.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)